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Gary S FiresteinAbstract
Rheumatoid arthritis is a complex disease where
predetermined and stochastic factors conspire to
confer disease susceptibility. In light of the diverse
responses to targeted therapies, rheumatoid arthritis
might represent a final common clinical phenotype
that reflects many pathogenic pathways. Therefore, it
might be appropriate to begin thinking about
rheumatoid arthritis as a syndrome rather than a
disease. Use of genetics, epigenetics, microbiomics,
and other unbiased technologies will probably permit
stratification of patients based on mechanisms of
disease rather than by clinical phenotype.DNA sequences account for a minority of risk and mightObserver la nature, et suivez la route qu’elle vous trace.
JJ Rousseau, quoted in [1].
Over 150 years ago, Garrod coined the term ‘rheumatoid
arthritis’ (RA) to distinguish it from other forms of arthritis,
most notably gout and acute rheumatism [1]. Years later,
disease subsets were further characterized based, in part,
on clinical manifestations such as erosions and nodules
or laboratory values such as autoantibodies in the blood.
For instance, patients with rheumatoid factors and anti-
citrullinated protein antibodies (ACPAs) tend to have more
severe disease and worse long-term outcomes than sero-
negative patients.
The broad range of genes associated with RA, the role of
the environment in disease initiation, and the diversity of
responses to targeted therapies necessitate a re-evaluation
of time-honored stratification based on carefully docu-
mented clinical phenotypes. Moreover, we should recon-
sider whether RA should be viewed as the disease that
Garrod described or whether it represents a final common
pathway of divergent mechanisms in an organ (synovium)
with a limited repertoire of responses. In this context, RA
could be thought of as a syndrome with multiple etiologic
events.Correspondence: gfirestein@ucsd.edu
Division of Rheumatology, Allergy, and Immunology, UC San Diego School
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2014RA susceptibility is determined, in part, by inherited risk
factors that are predetermined. The single nucleotide poly-
morphisms (SNPs) associated with RA are dispersed widely
across the genome, with notable concentration in genes
that participate in adaptive and innate immune responses
[2]. Multiple genome-wide association studies have identi-
fied scores of disease-associated SNPs. By far the greatest
genetic risk is conferred by the class II major histocompati-
bility gene HLA-DR, which participates in antigen presen-
tation to T lymphocytes [3]. The critical regions of the
encoded protein have been well characterized and are
located in and around the antigen-binding groove. How-
ever, the observation that identical twins only have perhaps
a 15% concordance rate for RA indicates that inherited
not be as important as other influences [4]. Put another
way, full diploid genome sequencing of patients ignores
over 80% of disease risk.
Many SNPs outside the major histocompatibility complex
also contribute to susceptibility, but their influence is much
lower, with relative risks typically <1.2 [5]. One need not
have all of these SNPs to develop RA; only a limited subset
are probably needed in the presence of the proper environ-
mental exposures. Individual and combinations of low-
penetrance susceptibility genes have not offered major
insights into the clinical phenotype, although it is still early
days for these complex analyses. The fact that various
combinations of genes and types of environmental stress
lead to the same phenotype suggests that we are not
looking at a single disease but at a process with multiple
pathways.
The “original sin” in ACPA-positive RA is probably due
to an interaction between disease-associated HLA-DR
genes and the environment, especially at mucosal surfaces
(reviewed in [6]). The first steps could be viewed as a
normal adaptive immune response against stress-induced
modification of peptides, most notably by citrullination.
Stochastic events such as smoking, infection, periodontitis,
lung inflammation, or the gut microbiome thus lead to
induce enzymes (for example, peptidyl arginine deiminases)
that alter peptides and produce neo-epitopes not en-
countered by the thymus during early development. ThisThe licensee has exclusive rights to distribute this article, in any medium, for 6
e, the article is available under the terms of the Creative Commons Attribution
by/2.0), which permits unrestricted use, distribution, and reproduction in any
ly cited.
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that the gastrointestinal flora in early RA might be unique,
with an overabundance of Provatella copri [7]. These
environmental differences could potentially contribute also
to altered polarization of T cells to the pathogenic T-helper
type 17 phenotype [8].
The autoreactive clones that recognize altered antigens
were not deleted during development and can respond
appropriately to the antigen. An array of citrullinated
peptides fit avidly into the HLA-DR binding groove and
activate T cells much more efficiently than the native
protein [9]. These early steps probably represent a normal
adaptive immune response against altered antigens rather
than true autoimmunity. Production of ACPAs directed
against a variety of peptides ensues. In the presence of a
second hit, such as immune complexes or other mecha-
nisms that activate innate immunity and prepare the syno-
vium, ACPAs gain access to the joint, engage complement,
and recruit inflammatory cells that amplify the response.
Ultimately, breakdown of tolerance and true autoimmunity
against the native proteins ensue, possibly by epitope
spread. Interestingly, recently described novel antibody
systems to other altered antigens associated with RA, such
as through carbamylation rather than citrullination [10],
could lead to a similar process.
The most persuasive argument that RA has multiple
pathways to the same phenotype is the diversity of
responses to highly specific immunotherapies. T-cell co-
stimulation blocker, B-cell depletion, tumor necrosis fac-
tor inhibitors, or interleukin-6 inhibitors demonstrate
similar clinical response rates; that is, about one-half ofCytokines        T cells             
TRAF1 PTPN22              
IL6ST                    CTLA4               
STAT4                   CCR6                
Anti-cytokine remission      
Genes plus enviro
TNF blocker response     T cell costimulatio
Figure 1 Simplified schema showing how genes might affect clinical
single nucleotide polymorphisms (SNPs) could be generally categorized int
(TNF), T cells, B cells, others in this version). A particular individual might on
SNPs cluster in one mechanism, such as TNF blocker (see bottom rows), th
pathway. If the SNPs are not enriched for any particular pathway, then the
but would be integrated with pathways that are enriched for epigenetic mpatients treated with any single agent have a major benefit
[11]. If a patient does not respond to one targeted agent, a
good response to another agent with a distinct mechanism
of action is only slightly less likely than in a biologic-naïve
patient [12].
Evaluation of genes or other analytes to stratify patients
based on their underlying pathogenesis rather than on
clinical phenotype could shed light on how the variable
responses occur. Figure 1 shows an example (which is
clearly a simplification), focusing only on gene associations.
In this model, a patient with clusters of disease-associated
SNPs enriched for tumor necrosis factor regulation, for
example, might be expected to be a tumor necrosis factor
responder. A B-cell genotype, a T-cell genotype, and so on,
would also provide clues on how to treat a patient. If no
particular clustering occurs and the gene associations
are spread across multiple pathways, then any individual
targeted therapy would have a low likelihood of success.
As attractive as this notion might be, RA is not that
simple and, despite individual studies with potential signals,
we cannot reliably predict which patients will respond to a
particular biologic despite evaluating many gene associa-
tions as well as studies of blood cytokines, synovial path-
ology, or serum autoantibody profiles. Success will probably
require integrating more sophisticated datasets that also
take into account many nongenetic influences, such as
epigenomics, microbiomics, proteomics, metabolomics, or
immunomics, to define the deep profile of a particular
individual’s version of RA. Initial studies examining poten-
tial pathogenic pathways focusing on DNA methylation in
RA synoviocytes or integrating DNA methylation and gene  B cells               Other
   BLK PADI4
    CD40 IRF5
                                   CD244
Non responder
nmental stress
n response   B cell depletion response
responses to targeted therapies. Various genes with associated
o various pathogenic mechanisms (for example, tumor necrosis factor
ly inherit a subset of each of these SNPs. If the majority of inherited
en the individual would have a response to the agent that targets this
patient would be a nonresponder. This schema only focuses on SNPs,
arks or other regulators of gene expression/function.
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how this information might begin to identify previously
unrecognized subsets [13-15]. Systems biology approaches
to nongenetic and genetic influences also permit applica-
tion of computational methods to test the effects of per-
turbing networks in silico. While this approach is still in its
infancy, it could ultimately decrease the need for biologic
validation of every potential target or could identify combi-
nations of therapies that will be additive or synergistic.
These observations suggest that RA might be thought of
as a collection of distinct mechanisms rather than a single
pathway; that is, as a syndrome rather than a disease. A
similar conceptual evolution has occurred with other
diseases, such as acute myelogenous leukemia, with a tran-
sition from phenotype or histologic diagnosis to segmenting
the disease by genotype. We face the reverse of past
progress in medicine, where a unifying cause ultimately
links many clinical phenotypes, such as the great imitator
syphilis. Instead, our understanding of RA as a clinical
phenotype is devolving into multiple pathogenic pathways.
RA might have a common entry point, such as adaptive
immune responses to altered peptides followed by immune
complexes and autoimmunity, but the subsequent byzan-
tine pathway to the clinical phenotype is so convoluted and
personalized that solving RA for a particular patient
requires a systems approach using multiple emerging
technologies.
We have come a long way from “acute rheumatism”, but
still have far to go before these pathogenic processes can be
meaningfully dissected. The therapeutic successes with the
average patient have been stunning, but we have reached
the limit of this traditional approach. We must begin the
process of deconvoluting RA using unbiased technology
and carefully integrating predetermined and stochastic
influences that lead to the syndrome we call RA.Note: This article is part of the collection ‘Why is there persistent
disease despite aggressive therapy of rheumatoid arthritis?’, edited
by Pierre Miossec. Other articles in this series can be found at
http://arthritis-research.com/series/residual.Abbreviations
ACPA: Anti-citrullinated protein antibody; RA: Rheumatoid arthritis;
SNP: Single nucleotide polymorphism.
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